

Curriculum Vitae

François BERGER

University Activities

MD Thesis	1990
Assistant neuro-oncologist	1994
Thesis (PhD) Physics	1995
Post doctoral fellowship in the Salk institut and F Gage Laboratory	1995-97
Masters of Science (HDR)	1998
Head of Neuro-oncology reseach group	1999
Professor of oncology and cell biology	2000

Scientific Responsibilities

Head of the Cell Biology Department in Joseph Fourier University Medical School

Head of the "Brain Nanomedicine" group in the INSERM INSERM Research Center U 836 (ex U 318).
Coordinator of the "transcriptomic and proteomic platform" (CHU Grenoble, Canceropole Rhône-alpes).

Head of the clinico-biological Neuro-oncology unit in Grenoble university hospital

Coordinator of the neuro-oncology Tissues bank of the CHU Grenoble hospital (DHOS and INSERM labelization 2003 and 2004)

Member of the Ethical board of Nano2life excellence project (2004)

Coordinator of the transcriptomic study of the etumour European integrated project (2004)

Member of the Ecopia scientific Board (2005)

Member of the Ligue National Contre le Cancer Scientific board (2005)

Coordinator of the French CIT3 GLIOMA CONSORTIUM (2005)

I benefit from a "Hospitalier contrat d'interface" providing a 50% clinical doctor for my clinical activity permitting me to be for 5 years at 100% for my research activity.

Publications and patents

1) Main Patents

a. International

Patent-1

Vimentine phosphorylée comme marqueur de l'agressivité et/ou l'invasivité des tumeurs.

Brevet français N° 04 09857 du 17 septembre 2004

Déposants : Genome express + INSERM

Inventeurs : A. Bouamrani, E. Gay, J.-P. Issartel, F. Berger

Patent -2

Apparatus and methods for obtaining a molecular fingerprint.

US application number 122427 du 31 janvier 2005

Déposant : INSERM

Inventeurs : A. Bouamrani, A-L Benabid, J.-P. Issartel, F. Berger

Patent -3

Procédé et système de détermination in vitro de la réactivité d'une entité d'intérêt sur un élément fonctionnel tridimensionnel

Demande de brevet français N° 0502308 du 8 mars 2005

Déposant : INSERM

Inventeurs : P Clement, F Berger

Brevet- 4

Use of compositions comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions PCT/CA 2005/000751 du 14 décembre 2005)

b-French

Brevet-5

Procédé de détection immunologique pour le dépistage des tumeurs et la caractérisation de leur sensibilité aux cytotoxiques. – EFFA1
Brevet français 0511954 du 25 novembre 2005
Déposants : Genome express + INSERM
Inventeurs : L Pelletier, S Marand, R Beugnot, JP Issartel, F Berger

Brevet-6

Procédé de détection immunologique pour le dépistage des tumeurs et la caractérisation de leur sensibilité aux cytotoxiques. MARK 3 – cible thérapeutique
Brevet français 0511958 du 25 novembre 2005
Déposants : Genome express + INSERM
Inventeurs : L Pelletier, S Marand, R Beugnot, JP Issartel, F Berger

2) 5 Main Publications related to the topic of the project

Apolipoprotein-A1: a serum marker of Polycythemia with high levels (>75%) of JAK2-V617F alleles
Proteomics accepted

A novel method of tissue collection and storage:Validation using SELDI-TOF MS analysis: R Machaalani, M Arlotto, K Waters, E Gozal, F Berger, M Dematteis. Clin Chem, in press.

Bouamrani A, Ternier J, Ratel D, Benabid AL, Issartel JP, Brambilla E, Berger F.

Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics.
Clin Chem. 2006 Nov;52(11):2103-6. 2006 Sep 21.

Bachelot T, Ratel D, Menetrier-Caux C, Wion D, Blay JY, Berger F. Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br J Cancer. 2006 Apr 10;94(7):1066-70.

Tropel P, Platet N, Platel JC, Noel D, Albrieux M, Benabid AL, Berger F.
Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells.
Stem Cells. 2006 Dec;24(12):2868-76. Epub 2006 Aug 10.

Berger F, Gay E, Pelletier L, Tropel P, Wion D.
Development of gliomas: potential role of asymmetrical cell division of neural stem cells.
Lancet Oncol. 2004 Aug;5(8):511-4.